Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8NFW8

UPID:
NEUA_HUMAN

ALTERNATIVE NAMES:
CMP-N-acetylneuraminic acid synthase

ALTERNATIVE UPACC:
Q8NFW8; Q96AX5; Q9NQZ0

BACKGROUND:
The enzyme N-acylneuraminate cytidylyltransferase, alternatively known as CMP-N-acetylneuraminic acid synthase, is pivotal in the biosynthesis of sialic acids. These acids are essential for the proper functioning of glycoproteins and glycolipids, influencing cell-cell interaction, immunity, and pathogen recognition.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of N-acylneuraminate cytidylyltransferase offers a pathway to novel therapeutic avenues. Its critical role in cellular mechanisms suggests potential targets for intervention in diseases where cell communication is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.